Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Otsuka’s Novel Samska Gets U.S. Advisory Committee Review

This article was originally published in PharmAsia News

Executive Summary

U.S. FDA's Cardiovascular and Renal Drugs Advisory Committee will meet June 25 to evaluate Otsuka Pharmaceutical's hyponatremia drug Samska (tolvaptan) for approval in patients with hypervolemic and euvolemic hyponatremia.

You may also be interested in...



U.S. FDA Panel Blesses Otsuka’s Hyponatremia Drug

The fate of Otsuka Pharmaceutical's Samska may have become somewhat clearer June 25, when a U.S. FDA advisory panel voted to recommend approval of the compound for hyponatremia, or subnormal sodium in the blood

U.S. FDA Panel Blesses Otsuka’s Hyponatremia Drug

The fate of Otsuka Pharmaceutical's Samska may have become somewhat clearer June 25, when a U.S. FDA advisory panel voted to recommend approval of the compound for hyponatremia, or subnormal sodium in the blood

FDA Accepts NDA For Otsuka’s Novel Hyponatremia Treatment

FDA has accepted Otsuka's new drug application for the investigational V2-vasopressin receptor antagonist tolvaptan, which could enter an increasingly crowded market

UsernamePublicRestriction

Register

LL021103

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel